{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:52:46Z","timestamp":1778158366505,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pamela and Nick Gelsomini Breast Surgical Oncology Fellowship Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1245\/s10434-021-10726-3","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:52:25Z","timestamp":1630457545000},"page":"972-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes"],"prefix":"10.1245","volume":"29","author":[{"given":"Olga","family":"Kantor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Means","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Grossmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanujit","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"10","key":"10726_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection versus no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA"},{"issue":"12","key":"10726_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol"},{"issue":"4","key":"10726_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"A Savolt","year":"2017","unstructured":"Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla\u2013surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10726_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297\u2013305.","journal-title":"Lancet Oncol"},{"issue":"1","key":"10726_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jamcollsurg.2015.02.035","volume":"221","author":"K Yao","year":"2015","unstructured":"Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ. Impact of the American College of Surgeons Oncology Group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast cancer. J Am Coll Surg. 2015;221(1):71\u201381.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10726_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-019-05243-7","volume":"176","author":"A Weiss","year":"2019","unstructured":"Weiss A, Lin H, Babiera GV, et al. Evolution in practice patterns of axillary management following mastectomy in patients with 1\u20132 positive sentinel nodes. Breast Cancer Res Treat. 2019;176(2):435\u201344.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10726_CR7","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1245\/s10434-018-6519-1","volume":"25","author":"M Moossdorff","year":"2018","unstructured":"Moossdorff M, Nakhlis F, Hu J, et al. The potential impact of AMAROS on the management of the axilla in patients with clinical T1-2N0 breast cancer undergoing primary total mastectomy. Ann Surg Oncol. 2018;25(9):2612\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10726_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.21873\/invivo.11689","volume":"33","author":"R Arisio","year":"2019","unstructured":"Arisio R, Borella F, Porpiglia M, et al. Axillary dissection versus no axillary dissection in breast cancer patients with positive sentinel lymph node: a single institution experience. In Vivo. 2019;33(6):1941\u20137.","journal-title":"In Vivo"},{"issue":"12","key":"10726_CR9","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1245\/s10434-018-6525-3","volume":"25","author":"S Grossmith","year":"2018","unstructured":"Grossmith S, Nguyen A, Hu J, et al. Multidisciplinary management of the axilla in patients with ct1-t2 n0 breast cancer undergoing primary mastectomy: results from a prospective single-institution series. Ann Surg Oncol. 2018;25(12):3527\u201334.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10726_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4143\/crt.2018.438","volume":"51","author":"JH Joo","year":"2019","unstructured":"Joo JH, Kim SS, Son BH, et al. Axillary lymph node dissection does not improve post-mastectomy overall or disease-free survival among breast cancer patients with 1\u20133 positive nodes. Cancer Res Treat. 2019;51(3):1011\u201321.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10726_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jamcollsurg.2011.03.034","volume":"213","author":"L Spiguel","year":"2011","unstructured":"Spiguel L, Yao K, Winchester DJ, et al. Sentinel node biopsy alone for node-positive breast cancer: 12-year experience at a single institution. J Am Coll Surg. 2011;213(1):122\u20138 (Discussion 128-9).","journal-title":"J Am Coll Surg"},{"issue":"13","key":"10726_CR12","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1245\/s10434-014-3814-3","volume":"21","author":"Y Fu","year":"2014","unstructured":"Fu Y, Chung D, Cao MA, Apple S, Chang H. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer? Ann Surg Oncol. 2014;21(13):4109\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10726_CR13","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1245\/s10434-012-2386-3","volume":"19","author":"S Milgrom","year":"2012","unstructured":"Milgrom S, Cody H, Tan L, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012;19(12):3762\u201370.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10726_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1245\/s10434-016-5605-5","volume":"24","author":"E FitzSullivan","year":"2017","unstructured":"FitzSullivan E, Bassett RL, Kuerer HM, et al. Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. Ann Surg Oncol. 2017;24(3):652\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10726_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ejso.2015.05.007","volume":"41","author":"CZ Li","year":"2015","unstructured":"Li CZ, Zhang P, Li RW, Wu CT, Zhang XP, Zhu HC. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41(8):958\u201366.","journal-title":"Eur J Surg Oncol"},{"key":"10726_CR16","unstructured":"National Comprehensive Cancer Network: Breast Cancer. Version 2.2021. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_blocks.pdf."},{"key":"10726_CR17","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1245\/s10434-020-09533-z","volume":"28","author":"O Kantor","year":"2021","unstructured":"Kantor O, Chang C, Yao K, et al. Uptake of breast cancer clinical trials at minority serving cancer centers. Ann Surg Oncol. 2021;28:4995\u20135004. https:\/\/doi.org\/10.1245\/s10434-020-09533-z.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10726_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10549-019-05520-5","volume":"180","author":"AB Tadros","year":"2020","unstructured":"Tadros AB, Moo TA, Stempel M, Zabor EC, Khan AJ, Morrow M. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. Breast Cancer Res Treat. 2020;180(1):197\u2013205.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10726_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clbc.2013.04.004","volume":"13","author":"A Savolt","year":"2013","unstructured":"Savolt A, Polgar C, Musonda P, et al. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients? Clin Breast Cancer. 2013;13(5):364\u201370.","journal-title":"Clin Breast Cancer"},{"key":"10726_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.radonc.2018.07.006","volume":"131","author":"ML Gregorowitsch","year":"2019","unstructured":"Gregorowitsch ML, Verkooijen HM, Houweling A, et al. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients. Radiother Oncol. 2019;131:221\u20138.","journal-title":"Radiother Oncol"},{"issue":"1","key":"10726_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/SLA.0000000000002033","volume":"267","author":"EG Wilkins","year":"2018","unstructured":"Wilkins EG, Hamill JB, Kim HM, et al. Complications in postmastectomy breast reconstruction: 1-year outcomes of the Mastectomy Reconstruction Outcomes Consortium (MROC) Study. Ann Surg. 2018;267(1):164\u201370.","journal-title":"Ann Surg"},{"issue":"1","key":"10726_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/SAP.0000000000001186","volume":"80","author":"AW Peled","year":"2018","unstructured":"Peled AW, Sears M, Wang F, et al. Complications after total skin-sparing mastectomy and expander-implant reconstruction: effects of radiation therapy on the stages of reconstruction. Ann Plast Surg. 2018;80(1):10\u20133.","journal-title":"Ann Plast Surg"},{"issue":"4","key":"10726_CR23","doi-asserted-by":"publisher","first-page":"djw259","DOI":"10.1093\/jnci\/djw259","volume":"109","author":"EP Mamounas","year":"2017","unstructured":"Mamounas EP, Liu Q, Paik S, et al. 21-Gene recurrence score and locoregional recurrence in node-positive\/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017;109(4):djw259.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10726_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2019.5559","volume":"6","author":"WA Woodward","year":"2020","unstructured":"Woodward WA, Barlow WE, Jagsi R, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer. JAMA Oncol. 2020;6(4):505\u201311.","journal-title":"JAMA Oncol"},{"key":"10726_CR25","unstructured":"ClinicalTrials.gov. Regional radiotherapy in biomarker low risk node positive breast cancer (TAILOR RT). NCT03488693. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03488693. Accessed 15 Mar 2021."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10726-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10726-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10726-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:07:50Z","timestamp":1641222470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10726-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10726"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10726-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A. King reports Speakers honoraria and advisory board participation for Exact Sciences (formerly Genomic Health); and Faculty, PrecisCA cancer information service. E.A. Mittendorf reports scientific advisory board participation for Exact Sciences (formerly Genomic Health).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}